While studies and assessments of GLP-1 AOMs, such as the cost-effectiveness study by the Institute for Clinical and Economic Review (ICER), 24 emphasize the potential for improved outcomes in obesity-related chronic diseases (e.g., heart disease, diabetes, osteoarthritis) and the potential related savings, the cost of AOMs must be paid up front, often exceeding the political or financial capacity of state legislatures to fund the program adequately
In case further glycemic control is still needed, the dose can be augmented to 1.8 mg daily
Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery
"Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction"
They can also be cheaper than brand-name medications
Innovative studies have demonstrated the feasibility of biodegradable microneedle patches incorporating GLP-1 analogs such as exenatide and liraglutide, achieving sustained glucose-lowering effects in preclinical models